Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
Rhea-AI Summary
Absci (Nasdaq: ABSI) will report its second quarter 2026 business updates and financial and operating results after market close on Tuesday, August 11, 2026. Management will host a webcasted conference call at 4:30 p.m. Eastern Time, with live and replay access via the company’s investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – ABSI
In the Jul 15 session, ABSI declined 4.59%, reflecting a moderate negative market reaction. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 23 | Earnings date notice | Neutral | -0.8% | Announced timing and webcast details for Q1 2026 results release. |
| Feb 24 | Earnings date notice | Neutral | +2.3% | Scheduled Q4 and full-year 2025 results release and investor webcast. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings-date notices for Absci have been followed by relatively small, mixed price moves, suggesting these scheduling updates alone have had limited directional impact.
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, Wash. and NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the second quarter 2026 after market close on Tuesday, August 11, 2026.
Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook.
Live audio of the webcast will be available on the company’s investor relations website at: investors.absci.com. The webcast will be archived and available for replay after the event.
About Absci
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201™, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern hair-loss. ABS-201 is also being investigated as a potential “best-in-class” therapeutic for endometriosis, a condition with significant unmet medical need and market potential. Absci is headquartered in Vancouver, WA, with AI Research Labs in New York City and Serbia, and an Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.
Absci® standard character mark, ABS-201™, and Integrated Drug Creation™ are trademarks and registered trademarks of Absci Corporation.
Investor Contact
Alexander D.H. Khan
Corporate Vice President
Head of Investor Relations
investors@absci.com
Media Contact
press@absci.com
